Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Argenteuil – page 283

3 430 clinical trials in Argenteuil, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Argenteuil at a glance
3 430
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 430 trials in Argenteuil

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, and Dexamethasone for Elderly Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

Acute myeloid leukaemia+1

Not recruiting

Study of ASTX727 and Donor Lymphocyte Infusions for Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia After Stem Cell Transplant

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Groupe Francophone Des Myelodysplasies

Study on the Effectiveness of Chemotherapy with Fluorouracil, Capecitabine, and Oxaliplatin for Patients with Small Bowel Adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Inhibrx Biosciences Inc.

Study on Durvalumab and Tremelimumab for Liver Cancer Patients Undergoing Electroporation Ablation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Renal failure

Not recruiting

Study Comparing Anakinra and Prednisone for Treating Gout Flare in Patients with Advanced Kidney Disease or Kidney Transplant

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study on the Safety and Effectiveness of Luveltamab Tazevibulin (STRO-002) for Infants and Children Under 12 with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:STRO-002
  • Sponsor:Sutro Biopharma Inc.

Hodgkin's disease+6

Not recruiting

Study of Cobolimab and Dostarlimab for Children and Young Adults with Newly Diagnosed or Relapsed/Refractory Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Effects of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Incyte Biosciences International S.a.r.l.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Argenteuil

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and various lymphomas, evaluating novel treatment combinations and maintenance therapies. Studies include investigations of follicular lymphoma and chronic lymphocytic leukemia treatments.

  • Multiple Myeloma Therapy Optimization
  • Lymphoma Treatment Advances
  • Novel Drug Combinations

Particular emphasis on improving patient outcomes through targeted therapies and immunological approaches.

02 Immunology and Infectious Diseases

Clinical trials examining treatments for invasive candidiasis and immune system disorders. Research includes studies on immunosuppression prevention and management in intensive care settings.

  • Antifungal Treatments
  • Immune System Modulation
  • Critical Care Interventions

Focus on developing more effective treatments for both acute and chronic immune conditions.

03 Respiratory and Inflammatory Conditions

Studies investigating treatments for asthma and severe respiratory infections, including community-acquired pneumonia. Research includes evaluation of new delivery systems and therapeutic approaches.

  • Asthma Management
  • Pneumonia Treatment
  • Respiratory Drug Delivery

Emphasis on improving treatment outcomes and patient quality of life through innovative therapeutic strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.